Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies

BACKGROUND: Full application of cytokines as oncoimmunotherapeutics requires identification of optimal regimens. Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions. Subcutaneous injection and continuous intravenous infusion fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubois, Sigrid P, Miljkovic, Milos D, Fleisher, Thomas A, Pittaluga, Stefania, Hsu-Albert, Jennifer, Bryant, Bonita R, Petrus, Michael N, Perera, Liyanage P, Müller, Jürgen R, Shih, Joanna H, Waldmann, Thomas A, Conlon, Kevin C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061813/
https://www.ncbi.nlm.nih.gov/pubmed/33883258
http://dx.doi.org/10.1136/jitc-2020-002193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061813/
https://www.ncbi.nlm.nih.gov/pubmed/33883258
http://dx.doi.org/10.1136/jitc-2020-002193

Ejemplares similares